National Bank of Canada
ZVRA icon

National Bank of Canada’s Zevra Therapeutics ZVRA Stock Holding History

National Bank of Canada’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$642 Hold
69
– – ﹤0.01% 2721
2025
Q4 		$617 Buy
69
+7
+11% +$66 ﹤0.01% 2677
2025
Q3 		$589 Sell
62
-32
-34% -$321 ﹤0.01% 2686
2025
Q2 		$828 Buy
+94
New +$763 ﹤0.01% 2724

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

National Bank of Canada's ZVRA Position: Q1 2026 in Review

National Bank of Canada held its Zevra Therapeutics (ZVRA) position steady in Q1 2026 at 69 shares worth $642. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

National Bank of Canada first reported a position in ZVRA in Q2 2025 and has held it in 4 quarters since. The position peaked at $828 in Q2 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • National Bank of Canada held 69 shares of Zevra Therapeutics worth $642 as of Q1 2026.
  • National Bank of Canada left its Zevra Therapeutics share count unchanged in Q1 2026.
  • Zevra Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2721 holding.
  • National Bank of Canada first reported a position in Zevra Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • National Bank of Canada's Zevra Therapeutics position peaked at $828 in Q2 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.